DODGE & COX: CVS HEALTH CORP (CVS): Quarterly 13F Position History
As of Q1 2026, DODGE & COX reported 51,780,116 shares of CVS HEALTH CORP (CVS), worth $3.7B and representing 2.0% of its 13F equity book. Quarter-over-quarter share count change: 10,729,872 (-17.2%) . The position first appeared in Q1 2016 and has been disclosed across 41 13F-HR filings in Pactolio's tracked window.
- 51,780,116Shares Held (Latest Filing)
- $3.7BReported Market Value (Latest Filing)
- 2.0%Portfolio Weight (% of 13F Equity Book)
- 10,729,872Quarter-over-Quarter Share Change
- -$1.2BQuarter-over-Quarter Value Change
- 73,459,122Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 51,780,116 | 10,729,872 | -17.2% | $3.7B | 2.0% | $71.8 |
| Q4 2025 | 62,509,988 | 10,666,598 | -14.6% | $5.0B | 2.7% | $79.4 |
| Q3 2025 | 73,176,586 | 112,180 | -0.2% | $5.5B | 3.0% | $75.4 |
| Q2 2025 | 73,288,766 | 170,356 | -0.2% | $5.1B | 2.8% | $69.0 |
| Q1 2025 | 73,459,122 | +3,353,223 | +4.8% | $5.0B | 2.8% | $67.8 |
| Q4 2024 | 70,105,899 | +7,075,209 | +11.2% | $3.1B | 1.8% | $44.9 |
| Q3 2024 | 63,030,690 | +1,347,347 | +2.2% | $4.0B | 2.2% | $62.9 |
| Q2 2024 | 61,683,343 | +20,670,800 | +50.4% | $3.6B | 2.2% | $59.1 |
| Q1 2024 | 41,012,543 | +10,599,153 | +34.9% | $3.3B | 1.9% | $79.8 |
| Q4 2023 | 30,413,390 | +3,690,408 | +13.8% | $2.4B | 1.5% | $79.0 |
| Q3 2023 | 26,722,982 | +10,698,560 | +66.8% | $1.9B | 1.3% | $69.8 |
| Q2 2023 | 16,024,422 | +3,417,573 | +27.1% | $1.1B | 0.7% | $69.1 |
| Q1 2023 | 12,606,849 | +5,962 | +0.0% | $936.8M | 0.6% | $74.3 |
| Q4 2022 | 12,600,887 | 871,885 | -6.5% | $1.2B | 0.8% | $93.2 |
| Q3 2022 | 13,472,772 | 236,945 | -1.7% | $1.3B | 1.0% | $95.4 |
| Q2 2022 | 13,709,717 | 360,565 | -2.6% | $1.3B | 0.9% | $92.7 |
| Q1 2022 | 14,070,282 | 543,390 | -3.7% | $1.4B | 0.9% | $101.2 |
| Q4 2021 | 14,613,672 | 676,550 | -4.4% | $1.5B | 0.9% | $103.2 |
| Q3 2021 | 15,290,222 | 432,852 | -2.8% | $1.3B | 0.8% | $84.9 |
| Q2 2021 | 15,723,074 | 441,911 | -2.7% | $1.3B | 0.9% | $83.4 |
| Q1 2021 | 16,164,985 | +204,512 | +1.3% | $1.2B | 0.9% | $75.2 |
| Q4 2020 | 15,960,473 | +77,629 | +0.5% | $1.1B | 0.9% | $68.3 |
| Q3 2020 | 15,882,844 | 118,894 | -0.7% | $927.6M | 0.8% | $58.4 |
| Q2 2020 | 16,001,738 | 4,862,218 | -23.3% | $1.0B | 1.0% | $65.0 |
| Q1 2020 | 20,863,956 | +368,385 | +1.8% | $1.2B | 1.3% | $59.3 |
| Q4 2019 | 20,495,571 | 357,601 | -1.7% | $1.5B | 1.2% | $74.3 |
| Q3 2019 | 20,853,172 | +162,868 | +0.8% | $1.3B | 1.1% | $63.1 |
| Q2 2019 | 20,690,304 | +842,140 | +4.2% | $1.1B | 0.9% | $54.5 |
| Q1 2019 | 19,848,164 | +3,799,275 | +23.7% | $1.1B | 0.9% | $53.9 |
| Q4 2018 | 16,048,889 | +923,203 | +6.1% | $1.1B | 1.0% | $65.5 |
| Q3 2018 | 15,125,686 | +15,125,686 | — | $1.2B | 0.9% | $78.7 |
| Q2 2018 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2018 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2017 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2017 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2017 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2017 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2016 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2016 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2016 | 0 | 2,630 | -100.0% | $0 | 0.0% | — |
| Q1 2016 | 2,630 | — | — | $273.0K | 0.0% | $103.8 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did DODGE & COX first disclose a CVS position in 13F-HR filings?
DODGE & COX first reported CVS HEALTH CORP (CVS) on its 13F-HR filing for the period ending 2016-03-31 (Q1 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was DODGE & COX's most recent quarter-over-quarter share-count change in CVS?
Between Q4 2025 and Q1 2026, DODGE & COX reduced its CVS position by 10,729,872 shares (-17.2%), leaving 51,780,116 shares at a market value of $3.7B.
Does the implied price-per-share represent DODGE & COX's cost basis in CVS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.